comparemela.com

Latest Breaking News On - Chronic business - Page 1 : comparemela.com

Alkem Labs launches affordable anti-epileptic drug in India

Alkem Labs launches affordable anti-epileptic drug in India Alkem Labs launches affordable anti-epileptic drug in India 15 March 2021 | News Source credit: Shutterstock Mumbai based Alkem Laboratories has announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of epilepsy in India. Brivasure, Alkem’s anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg Rs 79.50/strip, Brivasure 50mg 148.50/strip, Brivasure 75mg 230/strip, Brivasure 100mg 295/strip, post patent expiry of innovator product, of Brivaracetam as on February 21, 2021. The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial onset seizure with or without secondary generalisation. The drug has exhibited faster onset of action, efficacy with favourable safety profile.

Alkem makes Epilepsy Treatment more accessible & affordable with the launch of BRIVASURE (Brivaracetam)

Mumbai (Maharashtra) [India], March 15 (ANI/NewsVoir): Alkem Laboratories Ltd. (Alkem), one of India s leading pharmaceutical formulation development, manufacturing, and marketing companies in India, announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India. Epilepsy is a common neurological disorder. Of the 70 million persons with epilepsy (PWE) worldwide, nearly 12 million PWE are expected to reside in India; which contributes to nearly one-sixth of the global burden.1 Brivaracetam has shown promise in patients with epilepsy whose seizures persist despite adequate treatment. The drug offers improved seizure control with minimal safety risks for patients with epilepsy2 Alkem Laboratories Limited has introduced brand Brivasure, the brand of Brivaracetam, at an affordable price in India.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.